Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Lasa Supergenerics
Join Channel
Consolidated Standalone

Lasa Supergenerics

₹23.1 -0.1 | 0.5%

Market Cap ₹116 Cr.

Stock P/E -9.3

P/B 1

Current Price ₹23.1

Book Value ₹ 22.3

Face Value 10

52W High ₹41

Dividend Yield 0%

52W Low ₹ 20.1

Edit Ratio

Lasa Supergenerics Research see more...

Overview Inc. Year: 2016Industry: Pharmaceuticals & Drugs

Lasa Supergenerics Ltd is an India-based corporation engaged in the manufacturing of anthelmintics/veterinary API. The Company also manufactures bulk tablets. Its product categories consist of veterinary API merchandise, different API products, animal feed components and reagents for healing use. Its veterinary API merchandise consist of toldimphos sodium, triclabendazole, rafoxanide, closantel sodium and oxyclozanide. different API merchandise include povidone iodine, fluconazole, iodoquinol, gabapentin and furosemide. Its animal feed substances consist of potassium iodide, cobalt sulphate, sodium selenate, ethylediamine dihydroiodide and vanadyl sulphate. Its reagents for healing use include cetylpyridinium chloride, bismuth subsalicylate and sodium selenite.

Read More..

Lasa Supergenerics Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Lasa Supergenerics Quarterly Results

#(Fig in Cr.) Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
Net Sales 36 34 16 51 29 34 32 31 24 27
Other Income 0 0 0 0 0 0 1 0 0 0
Total Income 36 34 16 51 29 34 33 31 24 27
Total Expenditure 31 33 17 40 37 34 34 27 23 26
Operating Profit 5 1 -1 11 -8 -0 -2 4 1 1
Interest 0 -0 0 0 0 1 0 0 1 0
Depreciation 3 3 4 3 3 3 3 3 3 3
Exceptional Income / Expenses 0 -12 0 4 0 -2 0 0 0 0
Profit Before Tax 1 -14 -5 11 -11 -7 -5 1 -2 -2
Provision for Tax 0 -0 -0 -1 1 -0 -0 6 -2 -1
Profit After Tax 1 -14 -5 12 -12 -7 -5 -5 -0 -1
Adjustments 0 -0 0 0 0 -0 0 0 0 0
Profit After Adjustments 1 -14 -5 12 -12 -7 -5 -5 -0 -1
Adjusted Earnings Per Share 0.2 -3.4 -1.2 3 -3 -1.6 -1.2 -1 -0 -0.3

Lasa Supergenerics Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 0 199 244 170 167 202 137 130 114
Other Income 0 2 3 1 0 0 0 2 1
Total Income 0 201 247 170 167 203 137 131 115
Total Expenditure 0 153 202 159 137 155 121 136 110
Operating Profit 0 48 45 12 30 47 16 -5 4
Interest 0 12 11 8 8 2 0 4 1
Depreciation 0 8 18 19 17 16 15 13 12
Exceptional Income / Expenses 0 -26 0 0 0 0 -8 -20 0
Profit Before Tax 0 2 15 -16 5 29 -6 -42 -8
Provision for Tax 0 -0 3 -4 1 7 -1 -4 3
Profit After Tax 0 2 12 -12 4 23 -5 -39 -11
Adjustments 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 2 12 -12 4 23 -5 -39 -11
Adjusted Earnings Per Share 0 0 5.4 -5.3 0.9 5.6 -1.1 -7.7 -2.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -5% -8% -12% 0%
Operating Profit CAGR -131% NAN% NAN% 0%
PAT CAGR 0% NAN% NAN% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -5% -33% 1% NA%
ROE Average -28% -5% -5% -0%
ROCE Average -24% -3% -1% 3%

Lasa Supergenerics Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 0 75 117 105 141 159 158 118
Minority's Interest 0 0 0 0 0 0 0 0
Borrowings 0 81 60 46 14 0 0 0
Other Non-Current Liabilities 0 2 2 -3 -3 8 7 3
Total Current Liabilities 0 70 107 107 76 41 45 43
Total Liabilities 0 228 287 255 229 208 209 164
Fixed Assets 0 119 170 162 152 143 137 119
Other Non-Current Assets 0 30 8 8 1 1 6 6
Total Current Assets 0 79 109 86 76 64 66 39
Total Assets 0 228 287 255 229 208 209 164

Lasa Supergenerics Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 3 0 0 0 3 5 11
Cash Flow from Operating Activities -0 -3 40 41 14 41 9 -17
Cash Flow from Investing Activities 0 0 -44 -7 -2 -4 -3 11
Cash Flow from Financing Activities 0 0 4 -33 -10 -36 -0 -4
Net Cash Inflow / Outflow 0 -3 0 -0 2 1 6 -10
Closing Cash & Cash Equivalent 0 0 0 0 3 4 11 1

Lasa Supergenerics Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 5.4 -5.26 0.89 5.6 -1.06 -7.71
CEPS(Rs) 0 2010.1 13.34 3.18 5.16 9.49 1.83 -5.03
DPS(Rs) 0 0 0 0 0 0.25 0.25 0
Book NAV/Share(Rs) 0 0 51.32 46.05 34.78 39.07 31.51 23.61
Core EBITDA Margin(%) 0 20.86 16.78 6.52 17.91 23.33 11.68 -5.09
EBIT Margin(%) 0 6.33 10.81 -4.55 7.69 15.59 -4.43 -29.38
Pre Tax Margin(%) 0 0.98 6.2 -9.5 2.83 14.57 -4.48 -32.62
PAT Margin (%) 0 1.08 5.02 -7.09 2.17 11.25 -3.89 -29.81
Cash Profit Margin (%) 0 4.61 12.41 4.29 12.53 19.07 6.69 -19.45
ROA(%) 0 2.07 4.79 -4.44 1.5 10.43 -2.56 -20.71
ROE(%) 0 8.65 14.33 -10.81 2.94 15.17 -3.37 -27.97
ROCE(%) 0 14.45 12.8 -3.73 6.77 17.14 -3.41 -23.94
Receivable days 0 58.49 57.25 76.45 54.04 31.94 44.35 29.63
Inventory Days 0 55.96 56.19 79.46 63.18 39.28 38.27 35.78
Payable days 0 35.39 78.02 153.49 180.1 75.46 59.24 45.3
PER(x) 0 0 16.8 0 31.83 10.7 0 0
Price/Book(x) 0 0 1.77 0.5 0.82 1.53 1.32 0.78
Dividend Yield(%) 0 0 0 0 0 0.42 0.6 0
EV/Net Sales(x) 0 0.58 1.28 0.79 0.94 1.28 1.55 0.86
EV/Core EBITDA(x) 0 2.4 6.96 11.62 5.23 5.46 13 -23.53
Net Sales Growth(%) 0 0 22.53 -30.37 -1.37 21 -32.24 -5.51
EBIT Growth(%) 0 0 92.35 -129.04 266.6 145.38 -119.25 -526.76
PAT Growth(%) 0 0 422.35 -197.49 130.16 527.76 -123.41 -624.41
EPS Growth(%) 0 0 0 -197.49 116.95 527.75 -119 -624.41
Debt/Equity(x) -1.16 2.11 0.91 0.8 0.34 0.12 0.13 0.18
Current Ratio(x) 100 1.13 1.02 0.8 1 1.59 1.48 0.92
Quick Ratio(x) 100 0.66 0.62 0.51 0.65 1.16 1.22 0.59
Interest Cover(x) 0 1.18 2.34 -0.92 1.58 15.28 -93.74 -9.08
Total Debt/Mcap(x) 0 0 0.51 1.61 0.42 0.08 0.12 0.24

Lasa Supergenerics Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 45.01 43.78 43.78 43.78 43.78 53.65 53.65 53.65 53.65 53.65
FII 0.06 0 0.4 0 0 0 0 0 0.01 0.12
DII 0 0 0 0 0 0 0 0 0 0
Public 54.93 56.21 55.82 56.22 56.22 46.35 46.35 46.34 46.34 46.23
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 59.24 to 45.3days.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of -5% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Lasa Supergenerics News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!